Literature DB >> 21132705

Structural design, solid-phase synthesis and activity of membrane-anchored β-secretase inhibitors on Aβ generation from wild-type and Swedish-mutant APP.

Heinke Schieb1, Sebastian Weidlich, Georg Schlechtingen, Philipp Linning, Gary Jennings, Margit Gruner, Jens Wiltfang, Hans-Wolfgang Klafki, Hans-Joachim Knölker.   

Abstract

Covalent coupling of β-secretase inhibitors to a raftophilic lipid anchor via a suitable spacer by using solid-phase peptide synthesis leads to tripartite structures displaying substantially improved inhibition of cellular secretion of the β-amyloid peptide (Aβ). Herein, we describe a series of novel tripartite structures, their full characterization by NMR spectroscopy and mass spectrometry, and the analysis of their biological activity in cell-based assays. The tripartite structure concept is applicable to different pharmacophores, and the potency in terms of β-secretase inhibition can be optimized by adjusting the spacer length to achieve an optimal distance of the inhibitor from the lipid bilayer. A tripartite structure containing a transition-state mimic inhibitor was found to be less potent on Aβ generation from Swedish-mutant amyloid precursor protein (APP) than from the wild-type protein. Moreover, our observations suggest that specific variants of Aβ are generated from wild-type APP but not from Swedish-mutant APP and are resistant to β-secretase inhibition. Efficient inhibition of Aβ secretion by tripartite structures in the absence of appreciable neurotoxicity was confirmed in a primary neuronal cell culture, thus further supporting the concept.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21132705     DOI: 10.1002/chem.201002878

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  9 in total

1.  Insights into the Impact of a Membrane-Anchoring Moiety on the Biological Activities of Bivalent Compounds As Potential Neuroprotectants for Alzheimer's Disease.

Authors:  Liu He; Yuqi Jiang; Kai Liu; Victoria Gomez-Murcia; Xiaopin Ma; Alejandro Torrecillas; Qun Chen; Xiongwei Zhu; Edward Lesnefsky; Juan C Gomez-Fernandez; Bin Xu; Shijun Zhang
Journal:  J Med Chem       Date:  2018-01-05       Impact factor: 7.446

2.  Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.

Authors:  Gregory Hook; Jin Yu; Thomas Toneff; Mark Kindy; Vivian Hook
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

3.  Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia.

Authors:  Mirko Bibl; Marion Gallus; Volker Welge; Hermann Esselmann; Stefanie Wolf; Eckart Rüther; Jens Wiltfang
Journal:  J Neural Transm (Vienna)       Date:  2012-04-19       Impact factor: 3.575

4.  Generation of aggregation prone N-terminally truncated amyloid β peptides by meprin β depends on the sequence specificity at the cleavage site.

Authors:  Caroline Schönherr; Jessica Bien; Simone Isbert; Rielana Wichert; Johannes Prox; Hermann Altmeppen; Sathish Kumar; Jochen Walter; Stefan F Lichtenthaler; Sascha Weggen; Markus Glatzel; Christoph Becker-Pauly; Claus U Pietrzik
Journal:  Mol Neurodegener       Date:  2016-02-19       Impact factor: 14.195

Review 5.  The Metalloprotease Meprin β Is an Alternative β-Secretase of APP.

Authors:  Christoph Becker-Pauly; Claus U Pietrzik
Journal:  Front Mol Neurosci       Date:  2017-01-05       Impact factor: 5.639

6.  Solid-Phase Synthesis and Characterization of N-Terminally Elongated Aβ-3-x -Peptides.

Authors:  Isaak Beyer; Nasrollah Rezaei-Ghaleh; Hans-Wolfgang Klafki; Olaf Jahn; Ute Haußmann; Jens Wiltfang; Markus Zweckstetter; Hans-Joachim Knölker
Journal:  Chemistry       Date:  2016-05-11       Impact factor: 5.236

Review 7.  Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease.

Authors:  Thomas A Bayer; Oliver Wirths
Journal:  Acta Neuropathol       Date:  2014-05-07       Impact factor: 17.088

8.  Pharmacological Inhibition of Amyloidogenic APP Processing and Knock-Down of APP in Primary Human Macrophages Impairs the Secretion of Cytokines.

Authors:  Philipp Spitzer; Matthias Walter; Caroline Göth; Timo Jan Oberstein; Philipp Linning; Hans-Joachim Knölker; Johannes Kornhuber; Juan Manuel Maler
Journal:  Front Immunol       Date:  2020-09-03       Impact factor: 7.561

9.  ConjuPepDB: a database of peptide-drug conjugates.

Authors:  Balázs Balogh; Márton Ivánczi; Bilal Nizami; Tamás Beke-Somfai; István M Mándity
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.